GLYBURIDE
- Product NDC
- 75834-204
- 11-digit product format
- 758340204
- Labeler code
- 75834
- Product ID
- 75834-204_757b12d9-8efb-49ca-b8f7-7884535ca011
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- GLYBURIDE
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Nivagen Pharmaceuticals, Inc.
- Application
- ANDA203379
- Marketing category
- ANDA
- Marketing start
- 2019-01-25
- Substance
- GLYBURIDE
- Active strength
- 5 mg/1
- Pharmacologic classes
- Sulfonylurea Compounds [CS], Sulfonylurea [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- GLYBURIDE
- Listing expiration
- 2026-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| GLYBURIDE | 5 mg/1 |
Harmonized Identifiers#
Field, Values table| Field | Values |
|---|
| Unii | SX6K58TVWC |
| Rxcui | 197737, 310534, 310537 |
DailyMed Product Concepts#
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 75834-204-00 | GLYBURIDE | 1000 in 1 BOTTLE | TABLET | 1000 | | 2 |
| 75834-204-01 | GLYBURIDE | 100 in 1 BOTTLE | TABLET | 100 | | 2 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 75834-204 | GLYBURIDE TABLET [NIVAGEN PHARMACEUTICALS, INC.] | 2 | Current NDC, Legacy NDC, 2 package rows | 20210115_43c6f68b-5747-47c6-9538-51ef8c611db4.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 75834-204-00 | 75834020400 | 1000 TABLET in 1 BOTTLE (75834-204-00) | 1000 tablet | 2019-01-25 | 0000-00-00 | No | No | Current |
| 75834-204-01 | 75834020401 | 100 TABLET in 1 BOTTLE (75834-204-01) | 100 tablet | 2019-01-25 | 0000-00-00 | No | No | Current |